EAHAD, ISTH and WFH joint statement

Critical juncture in hemophilia treatment: global organizations issue urgent call to action

The ISTH, EAHAD, and WFH urge continued innovation and equitable access in hemophilia care

Also available in: Français Español

The International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the World Federation of Hemophilia (WFH) are issuing a statement and urgent call-to-action for a continued commitment to innovation and access in hemophilia care.

Over the past decade, hemophilia treatment has advanced significantly from traditional intravenous factor replacement to subcutaneous substitution therapies, rebalancing agents, and gene therapies.

These innovations offer significantly improved outcomes and quality of life for people with hemophilia, including those with mild or moderate disease, women, and individuals with related bleeding disorders.

In recent years, three gene therapies—ROCTAVIAN, HEMGENIX, and BEQVEZ—have received regulatory approval, marking a historic milestone. Concerningly, several companies have recently discontinued, halted or scaled back gene therapy programs, citing limited interest from the community and commercial uncertainty.

Claims of disinterest from the hemophilia community are misleading and jeopardize the progress of gene therapy advancements. Current slow adoption is significantly linked to commercial uncertainties, fragmented health-care systems, reimbursement challenges, long-term outcome uncertainties, and systemic barriers—not a lack of interest and/or need.

More than ever, scientific-medical societies and patient communities call for and support the development of safe, effective gene and other novel hemophilia therapies.

The ISTH, EAHAD, and WFH urge all stakeholders—industry, regulators, payors, funders, researchers, clinicians, and patients to:

  • Sustain research, investment and clinical developments in innovative and advanced therapies including gene therapies and non-replacement therapies
  • Optimize and expand access to existing treatments worldwide
  • Decrease unnecessary burdens in clinical development and drug approval processes
  • Develop clear, fair reimbursement frameworks
  • Strengthen global collaboration, research and education

The future of hemophilia care depends on collective action. Innovation and access to treatments must remain a priority so that all people with hemophilia wherever they live can benefit from safe, effective, and life-changing therapies.

To read the full statement and call to action, please click here (“Critical Juncture in the Development of Hemophilia Therapies A Statement and Call-to-Action from the International Society on Thrombosis and Haemostasis (ISTH)European Association for Haemophilia and Allied Disorders (EAHAD) World Federation of Hemophilia (WFH) for the importance of continued research into and development of effective and safe hemophilia treatments”).

In addition to ISTH, EAHAD and WFH, this statement is endorsed by the following organizations:

American Society of Gene & Cell Therapy
Asian-Pacific Society on Thrombosis and Hemostasis
Association for Haemophilia and Allied Disorders-Asia Pacific
European Haemophilia Consortium
European Society for Gene and Cell Therapy
Grupo Collectivo Latinoamericano de Hemostasis y Trombosis
Medical and Scientific Advisory Council (MASAC)
National Bleeding Disorders Foundation

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.